A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers.

"Declarations Ethics approval and consent to participateThe study complies with the Declaration of Helsinki. The study was approved by the Ethics Committee of St. Luke’s International Hospital (approval No. 22-R077). Consent for publicationWritten informed consent was obtained from all participants. Competing interestsNY received speaking fees from Bristol-Myers Squibb, Chugai Pharmaceutical, GlaxoSmithKline K.K., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co., Ltd, and Asahi Kasei Pharma.MO received speaking fees and/or honoraria from Eli Lilly and Company, Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, and Abbott, Japan. The other authors have no conflicts of interest to declare. Competing interests NY received speaking fees from Bristol-Myers Squibb, Chugai Pharmaceutical, GlaxoSmithKline K.K., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co., Ltd, and Asahi Kasei Pharma. MO received speaking fees and/or honoraria from Eli Lilly and Company, Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, and Abbott, Japan. The other authors have no conflicts of interest to declare."

"Funding No specific funding was received from any bodies in the public, commercial, or not-for-profit sectors to carry out the work described in this article."

"Trial registration Retrospectively registered."